FDA's Office of New Drugs Hosts Webinar on OCMQ v4.1, a Tool for Detecting Clinical Safety Signals
A Paradigm Shift in Clinical Safety Assessment
The FDA's Office of New Drugs (OND) held a webinar on OCMQs (OND Custom Medical Queries) to systematically detect adverse events in clinical trial data. This is a formal re-establishment of the system previously known as FDA Medical Queries (FMQs), in accordance with the revised administrative regulations (MAPP 6025.8) effective January 2025. The previous analysis based on the international medical terminology standard, MedDRA (Medical Dictionary for Regulatory Activities), was often too granular, potentially missing subtle but critical safety signals. Therefore, the FDA is leading the standardization of OCMQ to enhance the detection capabilities of adverse event data generated in clinical trials and to unify evaluation criteria.
OCMQ v4.1 Update and Enhanced Data Precision
The webinar focused on the latest OCMQ v4.1 version, updated in May 2026. OCMQ v4.1 provides a more refined analytical framework, reflecting the MedDRA v27.0 standard terminology. In particular, it is designed to allow adjustment of analytical sensitivity by dividing it into 'Narrow Component' and 'Broad Component' beyond simple searches. Furthermore, the algorithmic OCMQs, which comprehensively consider various data such as laboratory test results, medications taken, medical history, and the timing of adverse event occurrence, have been strengthened to maximize detection efficiency. This enables multidimensional adverse event detection from the clinical stage, allowing for proactive prevention of serious drug-related adverse reactions.
Predictability of New Drug Approval and Mitigation of CRL Risk
For global biotech and pharmaceutical companies, this standard guideline is expected to be a key milestone that determines the success of regulatory approvals. This is because the Standard Safety Tables and Figures (ST&Fs), which FDA reviewers use when reviewing New Drug Application (NDA) and Biologics License Application (BLA) submissions, are directly linked to OCMQ v4.1. If biotech companies introduce OCMQ standard analysis early in the Phase 1/2/3 clinical trial design, they can evaluate safety under consistent criteria with the FDA review team, preventing communication errors. This will significantly reduce the risk of receiving a Complete Response Letter (CRL) during the approval review process.
Enhanced Market Confidence and Biotech Risk Management
Standardized safety signal analysis can significantly affect the overall clinical success rate of new drug development and the post-market product reliability. Precise pre-approval adverse event detection prevents venture capital (VC) and investors from experiencing catastrophic financial disasters, such as the attachment of a Black Box Warning or early market withdrawal after launch. In particular, for early-stage biotech companies with highly sensitive pipeline values, proactively presenting standardized safety indicators can solidify market confidence in clinical data. Clinical design capabilities themselves act as an evaluation indicator that determines the asset value of the pipeline.
The FDA's introduction of OCMQ v4.1, a standard safety query, is a key regulatory tool that proactively controls the risk of Complete Response Letter (CRL) issuance by enhancing data analysis consistency from Phase 1 to Phase 3 clinical trials. As more than 30% of new drug approval rejections are due to failures in safety assessment, including adverse events, the v4.1 standard guide based on MedDRA v27.0 is a practical factor that shortens biotech development timelines. Whether OCMQ, linked to Standard Safety Tables and Figures (ST&Fs), is applied in advance is a factor that increases the reliability of clinical data compared to competing pipelines and existing standard of care (SoC), contributing to the formation of valuation for early-stage companies. As a result, OCMQ response capabilities will function as an intangible core competency that increases the risk-adjusted net present value (rNPV) of the pipeline when determining the terms of future large-scale licensing (L/O) agreements.